Featured Press Releases

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

  • 06 Nov 2024

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally...

Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

FDA Clears Roche

FDA Clears Roche's cobas® BV/CV Assay, Enabling Fast and Highly Accurate Diagnosis of Vaginitis

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

  • Tenpoint Therapeutics, Ltd.
  • 09 Nov 2026
BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

  • UCB
  • 09 Nov 2026
Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

  • Johnson & Johnson
  • 08 Nov 2026
Lilly and Hims & Hers expand access to Lilly

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

  • Hims & Hers
  • 06 Nov 2026
Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

  • Roche Diagnostics
  • 02 Nov 2026
Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

  • Superpower
  • 02 Nov 2026

Most Popular
November   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.